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Abstract. The rapid advancement of emerging genomics technologies and their
application for assessing safety and efﬁcacy of FDA-regulated products require a high
standard of reliability and robustness supporting regulatory decision-making in the FDA. To
facilitate the regulatory application, the FDA implemented a novel data submission program,
Voluntary Genomics Data Submission (VGDS), and also to engage the stakeholders. As part
of the endeavor, for the past 10 years, the FDA has led an international consortium of
regulatory agencies, academia, pharmaceutical companies, and genomics platform providers,
which was named MicroArray Quality Control Consortium (MAQC), to address issues such
as reproducibility, precision, speciﬁcity/sensitivity, and data interpretation. Three projects
have been completed so far assessing these genomics technologies: gene expression
microarrays, whole genome genotyping arrays, and whole transcriptome sequencing (i.e.,
RNA-seq). The resultant studies provide the basic parameters for ﬁt-for-purpose application
of these new data streams in regulatory environments, and the solutions have been made
available to the public through peer-reviewed publications. The latest MAQC project is also
called the SEquencing Quality Control (SEQC) project focused on next-generation
sequencing. Using reference samples with built-in controls, SEQC studies have demonstrated
that relative gene expression can be measured accurately and reliably across laboratories and
RNA-seq platforms. Besides prediction performance comparable to microarrays in clinical
settings and safety assessments, RNA-seq is shown to have better sensitivity for low
expression and reveal novel transcriptomic features. Future effort of MAQC will be focused
on quality control of whole genome sequencing and targeted sequencing.
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INTRODUCTION
A decade ago, microarrays were the mainstream geno-
mics technology used by the biomedical and pharmaceutical
research communities. Using this technique, a large expanse
of microarray data has been generated to support the drug
development process. For example, genomics data has been
used to evaluate drug safety and efﬁcacy in support of both
investigational new drug applications (IND) and new drug
applications (NDA). To facilitate the submission of genomics
data, the FDA created a novel data submission program
known as Voluntary Genomics Data Submission (VGDS) and
later extended it to Voluntary eXploratory Data Submission
(VXDS) so that other omics data could be included. The idea
behind this novel submission program was to facilitate FDA’s
communication with the sponsor and to identify the best ways
to apply omics data in regulatory application. The results of
these efforts have helped to develop the Guidance for
Industry on Pharmacogenomics (PGx) Data Submission (1).
The VXDS program encourages the sponsor to interact with
the FDA through submission of PGx data on a voluntary
basis. In addition to that, it provides a forum for scientiﬁc
discussions with the FDA outside of the regulatory review
process. This whole process has helped to establish a
regulatory environment within the FDA for receiving,
analyzing, and interpreting the PGx data.
In order to achieve the goals of the VXDS process, the
FDA created a data repository to keep track of all the data
submitted by the sponsors (2). The submitted information
was important to shape future regulatory policies regarding
PGx data submission and review. In an effort to create new
standards for receiving PGx data, the FDA sought to
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reproduce the analysis results and conclusions provided by
the sponsor. In addition to that, alternative analysis and
biological interpretation were also conducted and compared
with the sponsor’s analysis. These efforts established FDA’s
view for analysis and interpretation of PGx information.
During these efforts, it was identiﬁed that even the
slightest change in the statistical methods could lead to
substantial differences between the results from the sponsor
and those from the agency (1, 2). Differences in the statistical
analysis results led to discrepancies in biological interpreta-
tion. The high variations in analysis results were not just
related to the microarray technology, but were also observed
in most of the high-throughput screening technologies,
including those utilized in proteomics and metabolomics.
Whenever a new technology is introduced to assist in the
process of drug development, the biomedical and pharma-
ceutical research community tries to evaluate its potentials in
understanding the underlying mechanisms of drug efﬁcacy
and toxicity. These evaluation efforts enhance the under-
standing of the utility of the technologies, and the research
community learns their appropriate ﬁt-for-purpose applica-
tions. However, it may take 15–20 years for an innovative
technology to be translated to ﬁt-for-purpose applications in a
regulatory setting (3). It is thus of FDA’s interest to be
involved in the evaluation efforts in order to expedite such
translation. Through the efforts reviewed here, the FDA has
demonstrated its commitment to expedite the process of
incorporating the application of innovative technologies.
These efforts were carried out in collaboration with the
research community and stakeholders, with an emphasis on
promoting the optimization, reproducibility, and standardiza-
tion of the analysis protocol, data interpretation, and data
sharing.
MAQC CONSORTIUM
The MicroArray Quality Control (MAQC) consortium is
a community-wide effort led by the FDA to address the
above mentioned reproducibility concerns about the geno-
mics technologies. It was started about 10 years ago, involving
most FDA centers along with the international research
community and industry. Its objective was to analyze the
technical performance and utility of emerging molecular
technologies (e.g., microarrays, next-generation sequencing)
for clinical application and safety assessment. Throughout
MAQC efforts, there was a consistent emphasis on transpar-
ency. The results and conclusions were published in peer-
reviewed journals. The data generated during these efforts
has been made freely available to the public. Additionally,
some biological samples from which the data were generated
are also available from commercial vendors. The consortium
started in 2005 and by the end of 2014, three projects were
completed. During the course of these projects, three
different genomics technologies were evaluated. Under the
project MAQC 1 and 2, microarrays were evaluated. Various
issues related to the genome-wide genotyping arrays were
evaluated in the MAQC 2 project (4–15). The third MAQC
project, also known as SEquencing Quality Control (SEQC),
evaluated the RNA-seq technology. All three projects
evaluated the ﬁt-for-purpose application for clinical and
regulatory aspects of those genomics technologies. The entire
project published a total of 28 peer-reviewed articles (http://
www.fda.gov/ScienceResearch/BioinformaticsTools/
MicroarrayQualityControlProject/), and 11 of them were
published in Nature Biotechnology (4, 16–24). The paper
published from MAQC 1 project supported the FDA in the
development of BGuidance for Industry: Pharmacogenomics
Data Submission – Companion Guidance.^
The MAQC 1 project demonstrated inter- and intra-
platform reproducibility of gene expression measurements by
microarrays. The comprehensive study design was centered
on cross-site cross-platform performance evaluation through
the titration of two reference RNA samples. DNA microarray
results were compared with the quantitative PCR platforms
for gene expression, and high correlation was observed
between them. Additionally, external RNA controls for the
assessment of microarray performance were also evaluated,
along with various microarray data normalization techniques.
Importantly, MAQC 1 studies demonstrated that the combi-
nation of fold-change ranking and a non-stringent P value
cutoff led to increased consistency in differential gene
expression analysis and downstream biological interpretation.
The reference RNA samples chosen by the consortium have
since become standard material widely adopted by the
research community and the biotechnology industry for
laboratory proﬁciency testing and development of new
genomics technologies. As a natural progression, the
MAQC 2 project studied the development and reliability of
microarray-based predictive models for a variety of preclin-
ical and clinical endpoints. Over 30,000 models were devel-
oped by 36 data analysis teams using numerous model
building methods. Performance evaluation through a strictly
blind external validation process demonstrated the utility of
well-implemented internal cross validation in gauging the
model prediction performance. This carefully designed and
executed consortium effort with six large clinical and preclin-
ical microarray datasets demonstrated that reliable predictive
models can be developed when including sound and unbiased
cross-validation techniques in the process. We expect the
conclusions from the MAQC 2 project to be applicable to
models based on gene expression data from other high-
throughput technologies besides microarrays.
CHALLENGES FOR NGS
The next-generation sequencing (NGS) technologies
were ﬁrst introduced to the market in 2005 and have since
seen tremendous growth in both technology advancements
and research adoption. NGS has a wide spectrum of
application in biomedical research including but is not
limited to genome and exome sequencing, whole tran-
scriptome sequencing (i.e., RNA-seq), microRNA sequenc-
ing, and metagenomics. Some common challenges related to
NGS include data storage, transfer, sharing, analysis, and
visualization due to the sheer size of NGS datasets, which
are referred to as big data challenges. As a tool, the speciﬁc
application of NGS mainly deﬁnes the challenges and issues
associated with this technique. Our literature survey on the
use of NGS as a tool found that about 50% of the
applications are mainly related to the use of NGS to
understand genetic variations and their effect on disease
and drug response. About a quarter of the applications are
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related to RNA-seq while the rest of them are split into
various areas including microRNA sequencing and
metagenomics. Challenges and issues associated with hu-
man genome sequencing differs greatly from these associ-
ated with microRNA sequencing because the size of the
molecular object under investigation varies greatly, i.e., the
human genome has 3.2 billion base pairs in contrast to the
microRNA size of only 18–25 nucleotides.
THIRD PHASE OF MAQC PROJECT
Due to rapid advances in NGS technologies, the third
phase of the MAQC Project was initiated while the second
phase was still under the way. As mentioned above, this phase
is also known as the SEQC project with its focus on RNA-
seq. Over 180 participants from 73 different organizations
across 12 different countries participated in the SEQC
project. The project generated over 10 TB of data with over
100 billion reads. On submission of this dataset to the Gene
Expression Omnibus (GEO) repository in June 2014, it
represented around 6% of the total RNA-seq data in the
repository at that time. This rich data provides ample
opportunities for RNA-seq data analysis method develop-
ment. Under this project, four different datasets were
generated. The ﬁrst dataset was generated from six reference
samples. These reference samples were sequenced by various
laboratories using different RNA-seq platforms such as
Illumina HiSeq, Life Technologies SOLiD, and Roche 454.
The second dataset was composed of sequencing data for
about 500 neuroblastoma samples from pediatric patients.
The third dataset was from 100 rat liver samples. The last
dataset was a survey of rat transcriptomes using 11 different
organs across 4 different developmental stages for both male
and female rat. The SEQC project evaluated technical
performance, quality control, and cross lab and cross platform
reproducibility of RNA-seq. RNA-seq data was also com-
pared with data generated from the same samples by mature
microarray technologies. In addition to that, evaluations were
made on the use of RNA-seq for clinical applications and
safety assessments. The observations from these efforts were
published in 10 manuscripts (3, 22–30). Here we present ﬁve
major ﬁndings:
1. Relative measurement is more consistent than abso-
lute measurement.
We generated large datasets for six reference samples.
The samples were sequenced in 11 different laborato-
ries using various platforms (i.e., HiSeq, SOLiD, and
454) (27) with multiple library preparation replicates
for each sample at each laboratory. This study design
offered us an opportunity to evaluate cross lab and
cross platform consistency using the same sample. It
allowed us to study both intra-laboratory and cross
laboratory variability. Ideally, no gene would be
differentially expressed for the same sample when it
is sequenced with the same platform in different labs.
We observed that as many as 10,000 genes could pass
the statistical test to be considered as differentially
expressed. In contrary, when differentially expressed
genes (DEGs) from any pair of samples were
compared across laboratories and platforms, the
results were quite consistent (22). Thus, the analyses
demonstrated that relative measurement is much
more consistent and reproducible than the absolute
measurement.
2. RNA-seq vs microarrays.
Among its broad application, RNA-seq has two major
applications, ﬁrst is to determine DEGs by comparing
different conditions, e.g., treatment or disease status.
The second use is to develop gene expression-based
predictive models. However, microarrays have been
used for a long time to perform similar tasks.
Bioinformatics methods for analyzing and interpreting
the results from microarray data have been assessed
and established through the ﬁrst two MAQC projects.
In comparison, RNA-seq is a relatively new technol-
ogy and analysis methods are continuously being
developed. Thus, there is a great interest in the
community to compare microarrays and RNA-seq to
identify the beneﬁts of using RNA-seq over microar-
rays. To address the comparison, the SEQC project
implemented several studies to comprehensively as-
sess the difference and similarity between these two
technologies. In one of them, rat livers treated with 15
chemicals and matched controls were proﬁled with
both technologies and the DEGs detected for each
chemical were compared between the two technolo-
gies. Of note, these chemicals yielded a wide range of
treatment effect with a 10-fold difference between the
smallest and largest number of DEGs detected. With
this design, we could evaluate the concordance in
DEG analysis between RNA-seq and microarrays in
various levels of treatment effect. We found that the
concordance in DEGs between microarray and RNA-
seq was positively correlated with the strength of
treatment effect. Further analyses indicated that the
discordance was mostly due to the difference between
two platforms in quantifying the lowly expressed
genes. Speciﬁcally, for highly expressed genes, we
were able to achieve a concordance of about 75%
while the concordance was only 35% for lowly
expressed genes. Thus, the major difference between
microarrays and RNA-seq lies in their accuracy of
measuring lowly expressed genes. Further comparison
with quantitative PCR indicated that RNA-seq would
likely perform better than microarrays for lowly
expressed genes (24).
3. RNA-seq and Gene Discovery.
An important potential of RNA-seq is its ability to
discover novel, unannotated exon-exon junctions, which
is affected by read depth. On increasing the number of
reads from 10 million to 10 billion, both known genes
and novel junctions were continually detected.
Importantly, using quantitative PCR to validate some
selected novel junctions, we determined that over 80%
of them can be veriﬁed but their biological functions are
unknown (14). This observation opens the door for the
research community to peruse the area of increased read
depth analysis and identify new transcripts and evaluate
the contribution of such new transcripts or genes to
understand the underlying biological mechanisms re-
lated to disease and toxicity.
816 Xu et al.
4. Pipeline for RNA-seq.
One of the most asked questions in the research
community is which pipeline(s) is to be used for RNA-
seq data analysis. To address the question in the
context of big data, we evaluated 12 different pipe-
lines in this project. For each pipeline, there are
different parameter settings that lead to 278 major
permutations covering the common gene modes,
various quantiﬁcation, and normalization methods.
The comprehensive assessment was extremely costly
in terms of computational time. We identiﬁed DEGs
and compared the results with quantitative PCR and
also evaluated the performance of downstream pre-
diction models. We developed a composite metric
including accuracy, precision, sensitivity in detecting
lowly expressed genes, speciﬁcity in detecting DEGs,
and prediction performance to derive the best practice
for choosing RNA-seq data analysis pipelines. We
observed that the pipeline giving the better estimation
of the gene expression likely also gave better perfor-
mance in predictive modeling. Multiple pipeline
components jointly and signiﬁcantly impacted the
quantiﬁcation of gene expression and downstream
prediction performance. The manuscript is currently
under review at Nature Methods.
5. Legacy microarray data in the RNA-seq era.
Microarrays have been widely used in biomedical
research and drug development since 1995. Major
pharmaceutical companies usually generate thousands
of microarrays per year. In this analysis, we tried to
address whether RNA-seq-based gene signatures can be
applied to microarray data to leverage the investment
previously made. We tested three different classiﬁer
methods with three gene mapping categories to identify
the transferability of microarray information to the
RNA-seq data and vice versa. RNA-seq and microar-
rays were comparable for predictive models.
Importantly, signature genes were reciprocally transfer-
able between these two technology platforms.
Microarray models can accurately predict RNA-seq-
proﬁled samples. However, RNA-seq was less accurate
in predicting microarray-proﬁled samples, and the
performance was affected by modeling algorithms and
the gene mapping complexity (26).
PERSPECTIVES AND FUTURE DIRECTION
NGS technologies have emerged as an important tool for
many regulatory activities. Various FDA centers have en-
countered NGS data in regulatory science research and/or
regulatory applications. These include but are not limited to
(i) FDA oversight of NGS-based assays for diagnosis and
prognosis, (ii) applying NGS in food pathogen identiﬁcation
and outbreak detection, (iii) reviewing NGS data for drug
efﬁcacy and safety for both clinical and preclinical assess-
ments, and (iv) NGS as an improved tool for studying
immunogenicity of vaccines. More speciﬁcally for biological
products, NGS data can be utilized in various ways to support
their development with one current major use being the
identiﬁcation of microbial contaminations (31).
Building upon the success of the previous MAQC
projects, which were fundamental for the development of
FDA companion guidance to industry on pharmacogenomics
data submission, we are in the process of developing a follow-
up project, named SEquencing Quality Control Phase 2
(SEQC2). SEQC2 aims to develop quality control metrics
and benchmark bioinformatics approaches for the analysis of
the whole genome sequencing and targeted gene sequencing
data to achieve best practices, to develop standard analysis
protocols, and to apply these newer methods in regulatory
settings. The ultimate goal of SEQC2 is the development of
standards for using NGS data that will provide the FDA with
objective criteria and metrics for data quality assessment that
can be applied in regulatory settings and to provide informa-
tion for precision medicine.
In summary, the primary aim of these FDA-led efforts
for emerging genomics technologies is to engage the stake-
holders and research community for consensus building with
respect to the reliable use of genomics data with objective
criteria and assessment metrics for data quality and reliability,
which can be employed in the FDA for their ﬁt-for-purpose
application.
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